Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Identifieur interne : 003C01 ( Main/Exploration ); précédent : 003C00; suivant : 003C02Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Auteurs : Bradley J. Monk [États-Unis] ; Andrés Poveda [Espagne] ; Ignace Vergote [Belgique] ; Francesco Raspagliesi [Italie] ; Keiichi Fujiwara [Japon] ; Duk-Soo Bae [Corée du Sud] ; Ana Oaknin [Espagne] ; Isabelle Ray-Coquard [France] ; Diane M. Provencher [Canada] ; Beth Y. Karlan [États-Unis] ; Catherine Lhommé [France] ; Gary Richardson [Australie] ; Dolores Gallardo Rinc N [Mexique] ; Robert L. Coleman [États-Unis] ; Thomas J. Herzog [États-Unis] ; Christian Marth [Autriche] ; Arija Brize [Lettonie] ; Michel Fabbro [France] ; Andrés Redondo [Espagne] ; Aristotelis Bamias [Grèce] ; Marjan Tassoudji [Royaume-Uni] ; Lynn Navale [États-Unis] ; Douglas J. Warner [États-Unis] ; Amit M. Oza [Canada]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2014.
Descripteurs français
- KwdFr :
- Abstention thérapeutique, Adulte d'âge moyen, Angiopoïétine-1 (antagonistes et inhibiteurs), Angiopoïétine-2 (antagonistes et inhibiteurs), Femelle, Humains, Inhibiteurs de l'angiogenèse (administration et posologie), Inhibiteurs de l'angiogenèse (effets indésirables), Méthode en double aveugle, Oedème (), Paclitaxel (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Protéines de fusion recombinantes (administration et posologie), Protéines de fusion recombinantes (effets indésirables), Récidive tumorale locale (traitement médicamenteux), Sujet âgé, Survie sans rechute, Tumeurs de l'ovaire (traitement médicamenteux), Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux).
- MESH :
- administration et posologie : Inhibiteurs de l'angiogenèse, Paclitaxel, Protéines de fusion recombinantes.
- antagonistes et inhibiteurs : Angiopoïétine-1, Angiopoïétine-2.
- effets indésirables : Inhibiteurs de l'angiogenèse, Protéines de fusion recombinantes.
- traitement médicamenteux : Récidive tumorale locale, Tumeurs de l'ovaire, Tumeurs épithéliales épidermoïdes et glandulaires.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Abstention thérapeutique, Adulte d'âge moyen, Femelle, Humains, Méthode en double aveugle, Oedème, Sujet âgé, Survie sans rechute.
English descriptors
- KwdEn :
- Aged, Angiogenesis Inhibitors (administration & dosage), Angiogenesis Inhibitors (adverse effects), Angiopoietin-1 (antagonists & inhibitors), Angiopoietin-2 (antagonists & inhibitors), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Disease-Free Survival, Double-Blind Method, Edema (chemically induced), Female, Humans, Middle Aged, Neoplasm Recurrence, Local (drug therapy), Neoplasms, Glandular and Epithelial (drug therapy), Ovarian Neoplasms (drug therapy), Paclitaxel (administration & dosage), Recombinant Fusion Proteins (administration & dosage), Recombinant Fusion Proteins (adverse effects), Withholding Treatment.
- MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Paclitaxel, Recombinant Fusion Proteins.
- chemical , adverse effects : Angiogenesis Inhibitors, Recombinant Fusion Proteins.
- chemical , antagonists & inhibitors : Angiopoietin-1, Angiopoietin-2.
- chemically induced : Edema.
- drug therapy : Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Withholding Treatment.
Abstract
Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to the Tie2 receptor, and thereby inhibits angiogenesis. We aimed to assess whether the addition of trebananib to single-agent weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free survival.
DOI: 10.1016/S1470-2045(14)70244-X
PubMed: 24950985
Affiliations:
- Australie, Autriche, Belgique, Canada, Corée du Sud, Espagne, France, Grèce, Italie, Japon, Lettonie, Mexique, Royaume-Uni, États-Unis
- Arizona, Attique (région), Auvergne-Rhône-Alpes, Californie, Catalogne, Communauté de Madrid, Languedoc-Roussillon, Lombardie, Occitanie (région administrative), Rhône-Alpes, Région capitale de Séoul, Texas, État de New York
- Athènes, Barcelone, Lyon, Madrid, Milan, Montpellier, Séoul
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003655
- to stream PubMed, to step Curation: 003542
- to stream PubMed, to step Checkpoint: 003542
- to stream Ncbi, to step Merge: 001B48
- to stream Ncbi, to step Curation: 001B48
- to stream Ncbi, to step Checkpoint: 001B48
- to stream Main, to step Merge: 003C50
- to stream Main, to step Curation: 003C01
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.</title><author><name sortKey="Monk, Bradley J" sort="Monk, Bradley J" uniqKey="Monk B" first="Bradley J" last="Monk">Bradley J. Monk</name><affiliation wicri:level="2"><nlm:affiliation>Creighton University School of Medicine and University of Arizona Cancer Center at St Joseph's Hospital, Phoenix, AZ, USA. Electronic address: bradley.monk@chw.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Creighton University School of Medicine and University of Arizona Cancer Center at St Joseph's Hospital, Phoenix, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Poveda, Andres" sort="Poveda, Andres" uniqKey="Poveda A" first="Andrés" last="Poveda">Andrés Poveda</name><affiliation wicri:level="1"><nlm:affiliation>Fundacion Instituto Valenciano de Oncología, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Fundacion Instituto Valenciano de Oncología, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Leuven, KU Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospital Leuven, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Raspagliesi, Francesco" sort="Raspagliesi, Francesco" uniqKey="Raspagliesi F" first="Francesco" last="Raspagliesi">Francesco Raspagliesi</name><affiliation wicri:level="3"><nlm:affiliation>Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Fujiwara, Keiichi" sort="Fujiwara, Keiichi" uniqKey="Fujiwara K" first="Keiichi" last="Fujiwara">Keiichi Fujiwara</name><affiliation wicri:level="1"><nlm:affiliation>Saitama Medical University International Medical Center, Hidaka-Shi, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Saitama Medical University International Medical Center, Hidaka-Shi</wicri:regionArea><wicri:noRegion>Hidaka-Shi</wicri:noRegion></affiliation></author><author><name sortKey="Bae, Duk Soo" sort="Bae, Duk Soo" uniqKey="Bae D" first="Duk-Soo" last="Bae">Duk-Soo Bae</name><affiliation wicri:level="3"><nlm:affiliation>Samsung Medical Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Samsung Medical Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Oaknin, Ana" sort="Oaknin, Ana" uniqKey="Oaknin A" first="Ana" last="Oaknin">Ana Oaknin</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron Institute of Oncology, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name><affiliation wicri:level="3"><nlm:affiliation>Université Lyon-I, Centre Léon Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Lyon-I, Centre Léon Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Provencher, Diane M" sort="Provencher, Diane M" uniqKey="Provencher D" first="Diane M" last="Provencher">Diane M. Provencher</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre Hospitalier de l'Université de Montréal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Karlan, Beth Y" sort="Karlan, Beth Y" uniqKey="Karlan B" first="Beth Y" last="Karlan">Beth Y. Karlan</name><affiliation wicri:level="2"><nlm:affiliation>Cedars-Sinai Medical Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Medical Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lhomme, Catherine" sort="Lhomme, Catherine" uniqKey="Lhomme C" first="Catherine" last="Lhommé">Catherine Lhommé</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Richardson, Gary" sort="Richardson, Gary" uniqKey="Richardson G" first="Gary" last="Richardson">Gary Richardson</name><affiliation wicri:level="1"><nlm:affiliation>Cabrini Hospital, Malvern, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cabrini Hospital, Malvern, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Rinc N, Dolores Gallardo" sort="Rinc N, Dolores Gallardo" uniqKey="Rinc N D" first="Dolores Gallardo" last="Rinc N">Dolores Gallardo Rinc N</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Nacional de Cancerologia, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Instituto Nacional de Cancerologia, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Herzog, Thomas J" sort="Herzog, Thomas J" uniqKey="Herzog T" first="Thomas J" last="Herzog">Thomas J. Herzog</name><affiliation wicri:level="2"><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Columbia University Medical Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Marth, Christian" sort="Marth, Christian" uniqKey="Marth C" first="Christian" last="Marth">Christian Marth</name><affiliation wicri:level="1"><nlm:affiliation>Medical University Innsbruck, Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Medical University Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Brize, Arija" sort="Brize, Arija" uniqKey="Brize A" first="Arija" last="Brize">Arija Brize</name><affiliation wicri:level="1"><nlm:affiliation>Riga Eastern Clinical University Hospital, Riga, Latvia.</nlm:affiliation><country xml:lang="fr">Lettonie</country><wicri:regionArea>Riga Eastern Clinical University Hospital, Riga</wicri:regionArea><wicri:noRegion>Riga</wicri:noRegion></affiliation></author><author><name sortKey="Fabbro, Michel" sort="Fabbro, Michel" uniqKey="Fabbro M" first="Michel" last="Fabbro">Michel Fabbro</name><affiliation wicri:level="3"><nlm:affiliation>Regional Cancer Institute Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Regional Cancer Institute Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Redondo, Andres" sort="Redondo, Andres" uniqKey="Redondo A" first="Andrés" last="Redondo">Andrés Redondo</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>University Hospital La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bamias, Aristotelis" sort="Bamias, Aristotelis" uniqKey="Bamias A" first="Aristotelis" last="Bamias">Aristotelis Bamias</name><affiliation wicri:level="3"><nlm:affiliation>Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Tassoudji, Marjan" sort="Tassoudji, Marjan" uniqKey="Tassoudji M" first="Marjan" last="Tassoudji">Marjan Tassoudji</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Uxbridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Amgen, Uxbridge</wicri:regionArea><wicri:noRegion>Uxbridge</wicri:noRegion></affiliation></author><author><name sortKey="Navale, Lynn" sort="Navale, Lynn" uniqKey="Navale L" first="Lynn" last="Navale">Lynn Navale</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Oza, Amit M" sort="Oza, Amit M" uniqKey="Oza A" first="Amit M" last="Oza">Amit M. Oza</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24950985</idno><idno type="pmid">24950985</idno><idno type="doi">10.1016/S1470-2045(14)70244-X</idno><idno type="wicri:Area/PubMed/Corpus">003655</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003655</idno><idno type="wicri:Area/PubMed/Curation">003542</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003542</idno><idno type="wicri:Area/PubMed/Checkpoint">003542</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003542</idno><idno type="wicri:Area/Ncbi/Merge">001B48</idno><idno type="wicri:Area/Ncbi/Curation">001B48</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B48</idno><idno type="wicri:Area/Main/Merge">003C50</idno><idno type="wicri:Area/Main/Curation">003C01</idno><idno type="wicri:Area/Main/Exploration">003C01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.</title><author><name sortKey="Monk, Bradley J" sort="Monk, Bradley J" uniqKey="Monk B" first="Bradley J" last="Monk">Bradley J. Monk</name><affiliation wicri:level="2"><nlm:affiliation>Creighton University School of Medicine and University of Arizona Cancer Center at St Joseph's Hospital, Phoenix, AZ, USA. Electronic address: bradley.monk@chw.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Creighton University School of Medicine and University of Arizona Cancer Center at St Joseph's Hospital, Phoenix, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Poveda, Andres" sort="Poveda, Andres" uniqKey="Poveda A" first="Andrés" last="Poveda">Andrés Poveda</name><affiliation wicri:level="1"><nlm:affiliation>Fundacion Instituto Valenciano de Oncología, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Fundacion Instituto Valenciano de Oncología, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Leuven, KU Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>University Hospital Leuven, KU Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Raspagliesi, Francesco" sort="Raspagliesi, Francesco" uniqKey="Raspagliesi F" first="Francesco" last="Raspagliesi">Francesco Raspagliesi</name><affiliation wicri:level="3"><nlm:affiliation>Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Fujiwara, Keiichi" sort="Fujiwara, Keiichi" uniqKey="Fujiwara K" first="Keiichi" last="Fujiwara">Keiichi Fujiwara</name><affiliation wicri:level="1"><nlm:affiliation>Saitama Medical University International Medical Center, Hidaka-Shi, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Saitama Medical University International Medical Center, Hidaka-Shi</wicri:regionArea><wicri:noRegion>Hidaka-Shi</wicri:noRegion></affiliation></author><author><name sortKey="Bae, Duk Soo" sort="Bae, Duk Soo" uniqKey="Bae D" first="Duk-Soo" last="Bae">Duk-Soo Bae</name><affiliation wicri:level="3"><nlm:affiliation>Samsung Medical Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Samsung Medical Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Oaknin, Ana" sort="Oaknin, Ana" uniqKey="Oaknin A" first="Ana" last="Oaknin">Ana Oaknin</name><affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Vall d'Hebron Institute of Oncology, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name><affiliation wicri:level="3"><nlm:affiliation>Université Lyon-I, Centre Léon Bérard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université Lyon-I, Centre Léon Bérard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Provencher, Diane M" sort="Provencher, Diane M" uniqKey="Provencher D" first="Diane M" last="Provencher">Diane M. Provencher</name><affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre Hospitalier de l'Université de Montréal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Karlan, Beth Y" sort="Karlan, Beth Y" uniqKey="Karlan B" first="Beth Y" last="Karlan">Beth Y. Karlan</name><affiliation wicri:level="2"><nlm:affiliation>Cedars-Sinai Medical Center, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cedars-Sinai Medical Center, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lhomme, Catherine" sort="Lhomme, Catherine" uniqKey="Lhomme C" first="Catherine" last="Lhommé">Catherine Lhommé</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Richardson, Gary" sort="Richardson, Gary" uniqKey="Richardson G" first="Gary" last="Richardson">Gary Richardson</name><affiliation wicri:level="1"><nlm:affiliation>Cabrini Hospital, Malvern, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cabrini Hospital, Malvern, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Rinc N, Dolores Gallardo" sort="Rinc N, Dolores Gallardo" uniqKey="Rinc N D" first="Dolores Gallardo" last="Rinc N">Dolores Gallardo Rinc N</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Nacional de Cancerologia, Mexico City, Mexico.</nlm:affiliation><country xml:lang="fr">Mexique</country><wicri:regionArea>Instituto Nacional de Cancerologia, Mexico City</wicri:regionArea><wicri:noRegion>Mexico City</wicri:noRegion></affiliation></author><author><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Herzog, Thomas J" sort="Herzog, Thomas J" uniqKey="Herzog T" first="Thomas J" last="Herzog">Thomas J. Herzog</name><affiliation wicri:level="2"><nlm:affiliation>Columbia University Medical Center, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Columbia University Medical Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Marth, Christian" sort="Marth, Christian" uniqKey="Marth C" first="Christian" last="Marth">Christian Marth</name><affiliation wicri:level="1"><nlm:affiliation>Medical University Innsbruck, Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Medical University Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Brize, Arija" sort="Brize, Arija" uniqKey="Brize A" first="Arija" last="Brize">Arija Brize</name><affiliation wicri:level="1"><nlm:affiliation>Riga Eastern Clinical University Hospital, Riga, Latvia.</nlm:affiliation><country xml:lang="fr">Lettonie</country><wicri:regionArea>Riga Eastern Clinical University Hospital, Riga</wicri:regionArea><wicri:noRegion>Riga</wicri:noRegion></affiliation></author><author><name sortKey="Fabbro, Michel" sort="Fabbro, Michel" uniqKey="Fabbro M" first="Michel" last="Fabbro">Michel Fabbro</name><affiliation wicri:level="3"><nlm:affiliation>Regional Cancer Institute Montpellier, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Regional Cancer Institute Montpellier, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Redondo, Andres" sort="Redondo, Andres" uniqKey="Redondo A" first="Andrés" last="Redondo">Andrés Redondo</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>University Hospital La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bamias, Aristotelis" sort="Bamias, Aristotelis" uniqKey="Bamias A" first="Aristotelis" last="Bamias">Aristotelis Bamias</name><affiliation wicri:level="3"><nlm:affiliation>Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Tassoudji, Marjan" sort="Tassoudji, Marjan" uniqKey="Tassoudji M" first="Marjan" last="Tassoudji">Marjan Tassoudji</name><affiliation wicri:level="1"><nlm:affiliation>Amgen, Uxbridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Amgen, Uxbridge</wicri:regionArea><wicri:noRegion>Uxbridge</wicri:noRegion></affiliation></author><author><name sortKey="Navale, Lynn" sort="Navale, Lynn" uniqKey="Navale L" first="Lynn" last="Navale">Lynn Navale</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Amgen, Thousand Oaks, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Oza, Amit M" sort="Oza, Amit M" uniqKey="Oza A" first="Amit M" last="Oza">Amit M. Oza</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Angiogenesis Inhibitors (administration & dosage)</term><term>Angiogenesis Inhibitors (adverse effects)</term><term>Angiopoietin-1 (antagonists & inhibitors)</term><term>Angiopoietin-2 (antagonists & inhibitors)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Edema (chemically induced)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Neoplasms, Glandular and Epithelial (drug therapy)</term><term>Ovarian Neoplasms (drug therapy)</term><term>Paclitaxel (administration & dosage)</term><term>Recombinant Fusion Proteins (administration & dosage)</term><term>Recombinant Fusion Proteins (adverse effects)</term><term>Withholding Treatment</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abstention thérapeutique</term><term>Adulte d'âge moyen</term><term>Angiopoïétine-1 (antagonistes et inhibiteurs)</term><term>Angiopoïétine-2 (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (administration et posologie)</term><term>Inhibiteurs de l'angiogenèse (effets indésirables)</term><term>Méthode en double aveugle</term><term>Oedème ()</term><term>Paclitaxel (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Protéines de fusion recombinantes (administration et posologie)</term><term>Protéines de fusion recombinantes (effets indésirables)</term><term>Récidive tumorale locale (traitement médicamenteux)</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Tumeurs de l'ovaire (traitement médicamenteux)</term><term>Tumeurs épithéliales épidermoïdes et glandulaires (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Paclitaxel</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Recombinant Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Angiopoietin-1</term><term>Angiopoietin-2</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term><term>Paclitaxel</term><term>Protéines de fusion recombinantes</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Angiopoïétine-1</term><term>Angiopoïétine-2</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Edema</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Neoplasms, Glandular and Epithelial</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term><term>Protéines de fusion recombinantes</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Récidive tumorale locale</term><term>Tumeurs de l'ovaire</term><term>Tumeurs épithéliales épidermoïdes et glandulaires</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Withholding Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Abstention thérapeutique</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Méthode en double aveugle</term><term>Oedème</term><term>Sujet âgé</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to the Tie2 receptor, and thereby inhibits angiogenesis. We aimed to assess whether the addition of trebananib to single-agent weekly paclitaxel in patients with recurrent epithelial ovarian cancer improved progression-free survival.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Autriche</li><li>Belgique</li><li>Canada</li><li>Corée du Sud</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Italie</li><li>Japon</li><li>Lettonie</li><li>Mexique</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Arizona</li><li>Attique (région)</li><li>Auvergne-Rhône-Alpes</li><li>Californie</li><li>Catalogne</li><li>Communauté de Madrid</li><li>Languedoc-Roussillon</li><li>Lombardie</li><li>Occitanie (région administrative)</li><li>Rhône-Alpes</li><li>Région capitale de Séoul</li><li>Texas</li><li>État de New York</li></region><settlement><li>Athènes</li><li>Barcelone</li><li>Lyon</li><li>Madrid</li><li>Milan</li><li>Montpellier</li><li>Séoul</li></settlement></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Monk, Bradley J" sort="Monk, Bradley J" uniqKey="Monk B" first="Bradley J" last="Monk">Bradley J. Monk</name></region><name sortKey="Coleman, Robert L" sort="Coleman, Robert L" uniqKey="Coleman R" first="Robert L" last="Coleman">Robert L. Coleman</name><name sortKey="Herzog, Thomas J" sort="Herzog, Thomas J" uniqKey="Herzog T" first="Thomas J" last="Herzog">Thomas J. Herzog</name><name sortKey="Karlan, Beth Y" sort="Karlan, Beth Y" uniqKey="Karlan B" first="Beth Y" last="Karlan">Beth Y. Karlan</name><name sortKey="Navale, Lynn" sort="Navale, Lynn" uniqKey="Navale L" first="Lynn" last="Navale">Lynn Navale</name><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name></country><country name="Espagne"><noRegion><name sortKey="Poveda, Andres" sort="Poveda, Andres" uniqKey="Poveda A" first="Andrés" last="Poveda">Andrés Poveda</name></noRegion><name sortKey="Oaknin, Ana" sort="Oaknin, Ana" uniqKey="Oaknin A" first="Ana" last="Oaknin">Ana Oaknin</name><name sortKey="Redondo, Andres" sort="Redondo, Andres" uniqKey="Redondo A" first="Andrés" last="Redondo">Andrés Redondo</name></country><country name="Belgique"><noRegion><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name></noRegion></country><country name="Italie"><region name="Lombardie"><name sortKey="Raspagliesi, Francesco" sort="Raspagliesi, Francesco" uniqKey="Raspagliesi F" first="Francesco" last="Raspagliesi">Francesco Raspagliesi</name></region></country><country name="Japon"><noRegion><name sortKey="Fujiwara, Keiichi" sort="Fujiwara, Keiichi" uniqKey="Fujiwara K" first="Keiichi" last="Fujiwara">Keiichi Fujiwara</name></noRegion></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Bae, Duk Soo" sort="Bae, Duk Soo" uniqKey="Bae D" first="Duk-Soo" last="Bae">Duk-Soo Bae</name></region></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name></region><name sortKey="Fabbro, Michel" sort="Fabbro, Michel" uniqKey="Fabbro M" first="Michel" last="Fabbro">Michel Fabbro</name><name sortKey="Lhomme, Catherine" sort="Lhomme, Catherine" uniqKey="Lhomme C" first="Catherine" last="Lhommé">Catherine Lhommé</name></country><country name="Canada"><noRegion><name sortKey="Provencher, Diane M" sort="Provencher, Diane M" uniqKey="Provencher D" first="Diane M" last="Provencher">Diane M. Provencher</name></noRegion><name sortKey="Oza, Amit M" sort="Oza, Amit M" uniqKey="Oza A" first="Amit M" last="Oza">Amit M. Oza</name></country><country name="Australie"><noRegion><name sortKey="Richardson, Gary" sort="Richardson, Gary" uniqKey="Richardson G" first="Gary" last="Richardson">Gary Richardson</name></noRegion></country><country name="Mexique"><noRegion><name sortKey="Rinc N, Dolores Gallardo" sort="Rinc N, Dolores Gallardo" uniqKey="Rinc N D" first="Dolores Gallardo" last="Rinc N">Dolores Gallardo Rinc N</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Marth, Christian" sort="Marth, Christian" uniqKey="Marth C" first="Christian" last="Marth">Christian Marth</name></noRegion></country><country name="Lettonie"><noRegion><name sortKey="Brize, Arija" sort="Brize, Arija" uniqKey="Brize A" first="Arija" last="Brize">Arija Brize</name></noRegion></country><country name="Grèce"><region name="Attique (région)"><name sortKey="Bamias, Aristotelis" sort="Bamias, Aristotelis" uniqKey="Bamias A" first="Aristotelis" last="Bamias">Aristotelis Bamias</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Tassoudji, Marjan" sort="Tassoudji, Marjan" uniqKey="Tassoudji M" first="Marjan" last="Tassoudji">Marjan Tassoudji</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24950985
|texte= Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24950985" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |